<SEC-DOCUMENT>0001558370-22-014838.txt : 20221005
<SEC-HEADER>0001558370-22-014838.hdr.sgml : 20221005
<ACCEPTANCE-DATETIME>20221005080530
ACCESSION NUMBER:		0001558370-22-014838
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221005
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221005
DATE AS OF CHANGE:		20221005

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOPHARMA, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		221294549

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aytu-20221005x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/5/2022 10:55:00 AM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 7b758f78-127e-4740-ab1c-bdcd19f52d4d -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:aytu="http://www.aytubio.com/20221005" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityCentralIndexKey" id="Tc_0FvDMt_VzEuyfBED6ZL9gQ_1_1">0001385818</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:AmendmentFlag" id="Tc_J_sV1egjU0-eyXwewWwOjQ_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="aytu-20221005.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-05</xbrli:startDate><xbrli:endDate>2022-10-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_e2ff0742_da8f_4556_9095_537b9694bcef"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:DocumentType" id="Narr_U7P_S6H8SUK4s3oUvaGX7w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:14pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported):</b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_sTnsjR8QkUqNM2adtqC4ow"><b style="font-weight:bold;"> October 5, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityRegistrantName" id="Narr_r_g32VCNk0GCWwN4-FhrtA"><b style="font-weight:bold;">AYTU BIOPHARMA,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bc388308_3872_4b3b_a834_1bde8e559995"></a><a id="Tc_g3Gxe35vLECcM07HxEtxnQ_2_0"></a><a id="Tc_kSYq7JxRLE-3lOEckx15hg_2_2"></a><a id="Tc_-PpqumCilEGCzzBr6GzULw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:32.05%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:32.06%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:32.06%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:32.05%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_pimnQ0GloE6-pT0ayDUv3A_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:32.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityFileNumber" id="Tc_GUUdfelY00egVV9UO4R6Kw_1_2"><b style="font-weight:bold;">001-38247</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;width:32.06%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityTaxIdentificationNumber" id="Tc_lbflNfzIn0ihSYh3jP6xkg_1_4"><b style="font-weight:bold;">47-0883144</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:32.05%;border-top:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation)</p></td><td style="vertical-align:top;width:1.82%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:32.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:32.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityAddressAddressLine1" id="Narr_JgbGoaohY0235XlU6-l0Zg"><b style="font-weight:bold;">373 Inverness Parkway</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityAddressAddressLine2" id="Narr_1FOVKs6P1Uu2X1aEoz52Pg"><b style="font-weight:bold;">Suite&#160;206</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityAddressCityOrTown" id="Narr_c5BxPKGP306FcQc2JV_bSQ"><b style="font-weight:bold;">Englewood</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityAddressStateOrProvince" id="Narr_mUWym9l2nUa2P_oN77glTg"><b style="font-weight:bold;">CO</b></ix:nonNumeric><b style="font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:EntityAddressPostalZipCode" id="Narr_8ijrJqw610mTRmRYAHU-Lg"><b style="font-weight:bold;">80112</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(Address of principal executive offices, including Zip Code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:CityAreaCode" id="Narr_m1sZ1HGamEiB64-Dlo4RLw"><b style="font-weight:bold;">720</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:LocalPhoneNumber" id="Narr_l9JPCHzvNkeucAZO6RNwXw"><b style="font-weight:bold;">437-6580</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18.25pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_uJwEDhB0gUOMeTdNfE6Ntw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18.25pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_DHfSeKl3eUCZDp0eep-CbQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18.25pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_L2KOcHrO706Eog-1ZMJZFg"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18.25pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_2AtjwbKjwkGt7MCEJuqgXQ"><span style="font-family:'Segoe UI Symbol';font-size:10pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_810a9833_6b78_460d_b0c4_ce6f37bb1d34"></a><a id="Tc_NZ6EuslZMkimqeKnfkg1vA_1_0"></a><a id="Tc_qdca_ek6zECtp9jp7cjkbw_1_2"></a><a id="Tc_wB_e3OQVGUulYJcUyjiYzw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:17.78%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.5%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:40.38%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.54%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:17.78%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:1.78%;margin:0pt;padding:0.25pt 0pt 0.4pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:38.5%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:40.38%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:Security12bTitle" id="Tc_nAxiVNAYg0ik0lSO-adtig_2_0"><b style="font-weight:bold;">Common Stock, par value $0.0001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.54%;background:#cceeff;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.78%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" name="dei:TradingSymbol" id="Tc_Zxj11mJV-kyNk_7aqxIzvw_2_2"><b style="font-weight:bold;">AYTU</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.78%;background:#cceeff;margin:0pt;padding:0.25pt 0pt 0.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.5%;background:#cceeff;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_oW73E-zF6EOVKjJRr7C7Qw_2_4"><b style="font-weight:bold;">The NASDAQ Stock Market LLC</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 7.2pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_YGBNROXBpUGnqMPh6RLHog"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_5f73a7d2_a547_4378_8788_76be0a49c1e7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;<b style="font-weight:bold;white-space:pre-wrap;">7.01  Regulation FD Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 5, 2022 announced the continuing availability of Adzenys XR-ODT&#174; (amphetamine) extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall XR (mixed salts amphetamine) extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder (ADHD).</p><a id="_c3175430_fa0f_4648_b88e_59f11f3b7c65"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01 Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(d) Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.15%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.67%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:87.67%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.67%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="aytu-20221005xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated October 5, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.67%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_c30a6dd6_3d08_49cb_b3eb_21e272cfd3c4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:46.57%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AYTU BIOPHARMA,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.91%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 5, 2022</p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;white-space:nowrap;width:46.57%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#160;Mark Oki</p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mark Oki</p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.57%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aytu-20221005xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 10/5/2022 10:54:58 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt;">Exhibit 99.1</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><img src="aytu-20221005xex99d1001.jpg" alt="Text&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:56.35pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:138.7pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT<sup style="font-size:13.5pt;vertical-align:top;">&#174;</sup> in Response to Reported Generic Adderall<sup style="font-size:13.5pt;vertical-align:top;">&#174;</sup> XR Supply Disruptions</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XR</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reported Supply Disruptions of Adderall XR Generic Equivalents Have the Potential to Affect Patient Access to ADHD Medications</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ENGLEWOOD, CO / October 5, 2022</b> / Aytu BioPharma, Inc. (the Company or &#8220;Aytu&#8221;) (Nasdaq: AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, with a development pipeline addressing rare, pediatric-onset disorders, today announced the continuing availability of Adzenys XR-ODT&#174; (amphetamine) extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall&#174; XR (mixed salts amphetamine) extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder (ADHD). Adzenys XR-ODT is bioequivalent to Adderall XR and is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine. Adzenys XR-ODT is indicated for the treatment of ADHD in patients six years and older.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Aytu BioPharma has maintained consistent Adzenys XR-ODT production levels at its Grand Prairie, Texas manufacturing facility to ensure ongoing supply of Adzenys XR-ODT and has experienced no supply disruptions to date.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Adzenys XR-ODT has a twelve hour duration of action, has been FDA-approved as bioequivalent to Adderall XR, and is available in six equivalent strengths as follows:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:28%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="6" style="vertical-align:middle;width:72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Strength (mg)</b></p></td></tr><tr><td style="vertical-align:top;width:28%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adzenys XR-ODT</b></p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">6.3</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">9.4</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">12.5</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">15.7</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">18.8</p></td></tr><tr><td style="vertical-align:top;width:28%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adderall XR</b></p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">5</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">10</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">15</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">20</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">25</p></td><td style="vertical-align:top;width:12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">30</p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;">Visit <b style="font-weight:bold;">www.AdzenysXRODT.com</b> for more information including dose selection and titration schedule.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Josh Disbrow, Aytu BioPharma&#8217;s Chief Executive Officer, commented, &#8220;The widely reported supply disruptions associated with Adderall XR generics and other extended-release amphetamine medications has caused confusion and concern among the ADHD patients taking these medications, and we want to ensure the ADHD patient community knows that Adzenys XR-ODT supply remains uninterrupted. Further, </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">because Adzenys XR-ODT is available as a convenient orally disintegrating tablet and has been FDA-approved as bioequivalent to Adderall XR, it may be an appropriate option for some patients. Patients are encouraged to discuss any issues relating to medication availability with their physician to see if an alternative medication may be available.  Importantly, because Adzenys XR-ODT is available at retail pharmacies and through the Aytu RxConnect program pharmacies nationwide, filling Adzenys XR-ODT prescriptions is simple, and commercially-insured patients&#8217; co-payments are consistent and affordable.&#8221;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">To locate an Adzenys XR-ODT pharmacy in a patient&#8217;s area <b style="font-weight:bold;">please visit www.AytuRxConnect.com</b>. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">What is Adzenys XR-ODT?</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Adzenys XR-ODT is a central nervous system stimulant prescription medicine used for the treatment of ADHD in patients 6 years and older.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Important Safety Information</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:99.89%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:8pt 0pt 8pt 0pt;"><b style="font-weight:bold;">WARNING: ABUSE AND DEPENDENCE</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-style:italic;font-weight:bold;">See full prescribing information for complete boxed warning.</font></p><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:9.35pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">&#8226;</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">CNS stimulants, including ADZENYS XR-ODT, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. </b></p></div></div></div><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:9.35pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">&#8226;</b></p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy</b></p></div></div></div></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">CONTRAINDICATIONS</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Known hypersensitivity to amphetamine or other ingredients in Adzenys XR-ODT. Angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Taking a monoamine oxidase inhibitor (MAOI), or have taken an MAOI within the past 14 days. Hypertensive crisis can occur.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.27;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Adzenys XR-ODT is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Adzenys XR-ODT in a safe place to prevent misuse and abuse.  Selling or giving away Adzenys XR-ODT may harm others and is against the law.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Tell your doctor if you or your child has ever abused or been dependent on alcohol, prescription medicines, or street drugs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Who should not take Adzenys XR-ODT?</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Do not take Adzenys XR-ODT if you or your child is:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">allergic to amphetamine or any ingredients in Adzenys XR-ODT.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">taking or has taken an anti-depression medicine called monoamine oxidase inhibitor (MAOI) within the past 14 days.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Adzenys XR-ODT is a stimulant medicine. Tell your doctor about health conditions, including if:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">you or your child has any heart problems, heart defects, high blood pressure, or a family history of these problems. This is important because sudden death has occurred in people with heart problems or defects, and sudden death, stroke and heart attack have happened in adults. Your doctor should check for heart problems prior to prescribing Adzenys XR-ODT and will check you or your child&#8217;s blood pressure and heart rate during treatment.  Call the doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Adzenys XR-ODT.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">you or your child has mental problems, or a family history of suicide, bipolar illness, or depression. This is important because the following could occur: new or worse behavior and thought problems, new or worse bipolar illness, new psychotic symptoms (hearing voices, believing things that are not true, are suspicious) or new manic symptoms. Call the doctor right away if there are any new or worsening mental symptoms during treatment.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">you or your child has circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud&#8217;s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature and/or change color from pale, to blue, to red. Call the doctor right away if any signs of unexplained wounds appear on fingers or toes while taking Adzenys XR-ODT.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">your child is having slowing of growth (height and weight). Your child should have his or her height and weight checked often while taking Adzenys XR-ODT. The doctor may stop treatment if a problem is found during these check-ups.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">you or your child has kidney problems. Your doctor may lower the dose.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">you or your child is or plans to become pregnant.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">you or your child is breastfeeding or plans to breastfeed. You should not breastfeed while taking Adzenys XR-ODT.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">you or your child takes any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Adzenys XR-ODT and some medicines may interact with each other and cause serious side effects.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Do not start any new medicine while taking Adzenys XR-ODT without talking to your doctor first.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">What should I avoid while taking Adzenys XR-ODT?</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">drinking alcohol</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Common side effects of Adzenys XR-ODT include:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Decreased appetite and problems sleeping.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Children 6 &#8211; 12 Years also include: Stomach pain, extreme mood change, vomiting, nervousness, nausea, and fever.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Children 13 &#8211; 17 Years also include: Stomach pain and weight loss.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Adults also include: Dry mouth, headache, weight loss, nausea, anxiety, restlessness, dizziness, fast heart beat, diarrhea, weakness, and urinary tract infections.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">These are not all the possible side effects of Adzenys XR-ODT. Call your doctor for medical advice about side effects.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">For additional safety information, click here for Prescribing Information and Medication Guide and discuss with your doctor.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">To report suspected adverse reactions, contact Aytu BioPharma at 855-AYTU-BIO (855-298-8246). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt;">About ADHD</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">According to the Centers for Disease Control and Prevention, ADHD is one of the most common childhood disorders and can continue through adolescence and adulthood. In fact, ADHD is estimated to affect 5 percent of children and 2.5 percent of adults in the U.S3. Symptoms include inattentiveness, hyperactivity and impulsiveness. These patterns of behavior are seen in many settings (school, home, work) and can impact performance and relationships.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Stimulant medications such as amphetamine and methylphenidate are the standard of care for treating ADHD, and extended-release (XR) formulations of these medications allow for once-daily dosing. Most of the existing treatment formulations are tablets or capsules, which need to be swallowed intact or in some cases sprinkled on certain foods or fluids and ingested immediately. Orally disintegrating tablets differ from traditional tablets and capsules in that they are designed to disintegrate in the mouth, rather than being swallowed whole.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt;">About Aytu BioPharma, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company&#39;s prescription products include Adzenys XR-ODT&#174; (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT&#174; (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal&#174; ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor&#174; and Tri-Vi-Flor&#174;, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), an investigational PKC&#946; inhibitor being studied in the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Orphan Drug designation and Fast Track designation from the U.S. Food and Drug Administration and has received Orphan Drug designation from the European Commission. Aytu is also researching and advancing the development of the Healight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential application in the treatment of severe, difficult-to-treat respiratory infections. To learn more, please visit aytubio.com.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt;">Forward-Looking Statements</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as &#39;&#39;may,&#39;&#39; &#39;&#39;will,&#39;&#39; &#39;&#39;should,&#39;&#39; &#39;&#39;forecast,&#39;&#39; &#39;&#39;could,&#39;&#39; &#39;&#39;expect,&#39;&#39; &#39;&#39;suggest,&#39;&#39; &#39;&#39;believe,&#39;&#39; &#39;&#39;estimate,&#39;&#39; &#39;&#39;continue,&#39;&#39; &#39;&#39;anticipate,&#39;&#39; &#39;&#39;intend,&#39;&#39; &#39;&#39;plan,&#39;&#39; or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this press release, are forward-looking statements, including but not limited to any statements regarding the financial results and statements presented in this press release and during the business update call following its release. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the strength of our intellectual property portfolio, the anticipated start dates, durations and completion dates and the potential future results of ongoing and future AR101 clinical trials, the effectiveness of AR101 in treating VEDS and the anticipated future regulatory submissions and events related to AR101. We also refer you to (i) the risks described in &#39;&#39;Risk Factors&#39;&#39; in Aytu&#39;s Annual Report on Form 10-K, in Quarterly Reports filed on Form 10-Q, and in the other reports and documents it files with the Securities and Exchange Commission.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">Contacts for Investors:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Mark Oki, Chief Financial Officer</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Aytu BioPharma, Inc.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">moki@aytubio.com</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Robert Blum or Roger Weiss</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Lytham Partners</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">AYTU@lythampartners.com</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin:0pt;">Source: Aytu BioPharma, Inc.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aytu-20221005xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aytu-20221005xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !Q 18# 2(  A$! Q$!_\0
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MEG_M#2[A,C"[LX!'H>*_6?\ 9#^.]O\ '[X-Z5K9D4ZK;H+:_B'595'7\>M
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MC(W$9!KU:_\ VEOAK8^*],\.?\);IUQK&HR>5!!;3"3)]R.!0(^<?^"L7_)
M-,X_YBJ?^@UX_P#\$@W7^V/&:Y&[RXSBOJK]O_X8WGQ._9TUN#3HOM%[I^+V
M.,#DA>N/PK\Q_P!B#]HRW_9R^+8O-863^P[]/LM[M&3%S]['L:!K8_<JBN(\
M-?&WP'XNTN'4-+\6Z1<6\JAP3>1JP'N"<BN!^,G[9OPP^#FC37-YXCM-4OPI
M\FPTZ59GD;L/E.!02?''_!7TC^VO!8W+GRI/ESSUKU?_ ().?\D3U;_K_/\
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M;VBL'?3M-)=Y!Z,YQC]:_2/Q)XSTKPKX?_MJ_F9;#"D/&A<MNZ8 ZYK"\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>aytu-20221005.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/5/2022 10:55:04 AM-->
<!--Modified on: 10/5/2022 10:55:04 AM-->
<xsd:schema targetNamespace="http://www.aytubio.com/20221005" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:aytu="http://www.aytubio.com/20221005" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.aytubio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20221005_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aytu-20221005_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>aytu-20221005_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/5/2022 10:55:04 AM-->
<!--Modified on: 10/5/2022 10:55:04 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>aytu-20221005_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/5/2022 10:55:04 AM-->
<!--Modified on: 10/5/2022 10:55:04 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="aytu-20221005.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.aytubio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.aytubio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638005641048795021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638005641048795021" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638005641048795021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638005641048795021" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638005641048795021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638005641048795021" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638005641048795021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638005641048795021" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638005641048795021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638005641048795021" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638005641048805019" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638005641048805019" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638005641048805019" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638005641048805019" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638005641048805019" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638005641048805019" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638005641048805019" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638005641048805019" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638005641048805019" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638005641048805019" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638005641048805019" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638005641048805019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638005641048805019" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638005641048815027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638005641048815027" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638005641048815027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638005641048815027" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638005641048815027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638005641048815027" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638005641048815027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638005641048815027" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638005641048815027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638005641048815027" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638005641048815027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638005641048815027" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139945847970416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 05, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  05,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU BIOPHARMA,&#160;INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-0883144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">373 Inverness Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite&#160;206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Englewood<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">437-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>aytu-20221005x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aytu-20221005.xsd" xlink:type="simple"/>
    <context id="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2022-10-05</startDate>
            <endDate>2022-10-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_0FvDMt_VzEuyfBED6ZL9gQ_1_1">0001385818</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_J_sV1egjU0-eyXwewWwOjQ_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_U7P_S6H8SUK4s3oUvaGX7w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_sTnsjR8QkUqNM2adtqC4ow">2022-10-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_r_g32VCNk0GCWwN4-FhrtA">AYTU BIOPHARMA,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_pimnQ0GloE6-pT0ayDUv3A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_GUUdfelY00egVV9UO4R6Kw_1_2">001-38247</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_lbflNfzIn0ihSYh3jP6xkg_1_4">47-0883144</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_JgbGoaohY0235XlU6-l0Zg">373 Inverness Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_1FOVKs6P1Uu2X1aEoz52Pg">Suite&#160;206</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_c5BxPKGP306FcQc2JV_bSQ">Englewood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_mUWym9l2nUa2P_oN77glTg">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_8ijrJqw610mTRmRYAHU-Lg">80112</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_m1sZ1HGamEiB64-Dlo4RLw">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_l9JPCHzvNkeucAZO6RNwXw">437-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_uJwEDhB0gUOMeTdNfE6Ntw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_DHfSeKl3eUCZDp0eep-CbQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_L2KOcHrO706Eog-1ZMJZFg">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_2AtjwbKjwkGt7MCEJuqgXQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_nAxiVNAYg0ik0lSO-adtig_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_Zxj11mJV-kyNk_7aqxIzvw_2_2">AYTU</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Tc_oW73E-zF6EOVKjJRr7C7Qw_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw"
      id="Narr_YGBNROXBpUGnqMPh6RLHog">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1S:Q:=<<LU_P37K]Z)RC5S+#G53/>LN8(:]I(O3(V1J3O7=='6U92O65S)B
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M$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( *Y 1567BKL<P
M !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6
MH@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.
MD4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,
M<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW'
M]I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ KD!%
M51PX9>H_ 0  / (   \   !X;"]W;W)K8F]O:RYX;6R-4<MNPD ,_)75?D 3
M4(M41+B4/I"J%I6*^Y)UB,4^(J\#+5]?)U%4I%YZ\GILC6=F%^=(QWV,1_7E
M74B%KIF;>9:EL@9OTDUL(,BDBN0-2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#
MV743&4K&& 3L@!W".?W.NU:=,.$>'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$
MP,9M2XK.%7HR#'9 C.4?>-N)_#3[U"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/
M7<OQ"1T#K0S#,\6VP7#H:,1%=F6CSV&L0XAS^D^,L:JPA%4L6P^!AQP)7"<P
MI!J;I%4P'@H]KB@3K'H,+"&I=1BH9+=S*J?7=G#-(O<J0YJC#&AM!^&C6@L5
M!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0    (
M *Y 154D'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_
M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ
M0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,
MEJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
M    " "N0$5599!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RM
MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>
MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0
MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2H
MN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%
M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D
M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6
M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( *Y 154'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ KD!%5=V,
MK^+N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ KD!%59E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "N0$55F1MH<7$$  !%
M$0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ KD!%59^@&_"Q @  X@P   T              ( !M P
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "N0$55EXJ[',     3 @  "P
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52P4&      D "0 ^ @  %!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="aytu-20221005x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aytubio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="aytu-20221005x8k.htm">aytu-20221005x8k.htm</File>
    <File>aytu-20221005.xsd</File>
    <File>aytu-20221005_lab.xml</File>
    <File>aytu-20221005_pre.xml</File>
    <File>aytu-20221005xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aytu-20221005x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "aytu-20221005x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aytu-20221005_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aytu-20221005_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aytu-20221005.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "aytu",
   "nsuri": "http://www.aytubio.com/20221005",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aytu-20221005x8k.htm",
      "contextRef": "Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "aytu-20221005x8k.htm",
      "contextRef": "Duration_10_5_2022_To_10_5_2022_zPYqDYwyXUilITbpVTJYJw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.aytubio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-22-014838-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-014838-xbrl.zip
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M*,@*14OATO=8%ZK<#:3=+DHW[G;D@=B2O[_.WLKVOOL?4$L#!!0    ( *Y
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M Z$<^5%M9L/1T:&&/:_;41K=5O8XU^J<RK[D=&[QT:4R7D)VCCL-!?K0>-@
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MN7JY#9)1Y%VTC8<NF(- N4UV9O,;!ZHFV*>9ZV!*3!'T8YKXW:,F"M3,/(#
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M,1[#2M\!Y-]^T]L]IG_.A FTS!!KC.=6)1SAB.,9&XM4Z(KD8S5E@4I',A3
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M(X::5F+?2)?=7.9S8CXEEG]*;"")V5C"6DJ^W#9!1#EAD4I0,2A]OU.B"#Z
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M=2TR,#(R,3 P-7@X:RYH=&U02P$"% ,4    " "N0$558MNNB7 :  "VD@
M&               @ &](0  87ET=2TR,#(R,3 P-7AE>#DY9#$N:'1M4$L%
3!@     %  4 30$  &,\      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
